Takeda expands Ireland site to up production of cancer drug Ninlaro

Takeda is expanding API production for its new multiple myeloma drug with a new plant in Ireland. 

Japan’s Takeda, which expects its new multiple myeloma drug to be a big performer, is expanding API production for it with a new plant in Ireland. 

The company will invest €40 million ($42.8 million) in a new facility at its Grange Castle site in Dublin, primarily to manufacture Ninlaro, Business World reports. The cancer drug was approved in the U.S. last year and recently won backing from the European Medicines Agency.

The company will build a standalone high-containment production facility just for the drug; the expansion is expected to lead to the addition of 40 jobs at the site. 

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Chief Executive Christophe Weber recently told investors that he expects Ninlaro to be Takeda's best-selling cancer drug, outperforming current blockbuster Velcade. It is performing better in the U.S. than had been expected, and after the EU's recent reversal of an earlier rejection, Takeda will possibly launch Ninlaro in the EU next year.

Ninlaro is the first orally active proteasome inhibitor to reach the market and is making headway against injectables such as Takeda's own market-leading Velcade and Amgen's currently underperforming Kyprolis (carfilzomib). It had sales of about $125 million in the first 6 months of the fiscal year, despite what Weber said is a "very limited" label claim. Ninlaro is approved only for use in combination with lenalidomide and dexamethasone in patients who have received at least one prior therapy.

This is the second significant manufacturing expansion announced by the Japanese company within a week. It is also investing €100 million ($106 million) to build a vaccine manufacturing site in Singen, Germany, as part of a big push into the development of a vax against dengue fever.

Suggested Articles

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.